Acquisition Announced
Samsung Biologics Co. acquisition of PolyPeptide Group AG
CHF 1.5bn equity value
Announced 19 Jul 2026 · SIX: PPGN · CHF 44.31 cash per share · 40% premium
Advisers
PolyPeptide Group AG
Target
Not disclosed
Samsung Biologics Co.
Acquirer
- Financial adviser
- Legal adviser
- Tax adviser
- EY
(as Ernst & Young Han Young) - Information agent
- Sodali
- Target
- PolyPeptide Group AG
- Acquirer
- Samsung Biologics Co.
- Target based in
- Switzerland
- Buyer based in
- South Korea
- Sector
- Pharma Services
- Tags
- Pharma Services, Contract Manufacturing, Pharmaceutical Manufacturing
Similar deals
- Bora Pharmaceuticals Co. acquisition of MacroGenics GMP manufacturing site and CDMO operations May 2026 · US$123m · Pharmaceutical Manufacturing
- CordenPharma acquisition of AmbioPharm May 2026 · Pharma Services
- Apax Partners acquisition of Gerresheimer global Primary Packaging Plastics business Jul 2026 · US$1.7bn · Packaging
- Webster Equity Partners acquisition of Lifecore Biomedical Sep 2026 · US$664m · Pharma Services
- BC Partners stake in InfoRLife SA Jul 2026 · Pharma Services
Sources
- 19 Jul 2026 Press release (PR Newswire), Samsung Biologics announces all-cash offer to acquire PolyPeptide, accelerating multi-modality strategy and expanding global network across U.S., Europe, and India prnewswire.com
- 31 Aug 2026 Press release (PR Newswire), Samsung Biologics publishes prospectus for PolyPeptide public tender offer prnewswire.com
